ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
Condition(s): Multiple Myeloma; Hematological Neoplasms Last Updated: November 4, 2010Terminated